MedAvail Holdings, Inc. reaffirmed earnings guidance for the full year 2023. MedAvail is reaffirming its prior guidance for the full year 2023. In addition, the Company has substantially completed its disposition of its previous retail pharmacy business as of March 31, 2023.

The following comparison excludes discontinued operations. The company expects total revenue for the pharmacy technology business to be approximately $3 million, which would represent greater than 100% growth over 2022 pharmacy technology revenue of $1.4 million. MedAvail further expects full-year 2023 gross margins to be in excess of 60%.